The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BITRF | -75.41% | -95.2% | -45.46% | -98% |
| S&P | +15.58% | +78.13% | +12.24% | +349% |
Biotron Ltd. operates as a clinical stage biotechnology company. It engages in developing and commercializing a novel small molecule approach that treats serious viral disease. The firm's technology targets viroporin proteins, which enables the pathogenicity of a number of viruses including hepatitis C, HIV-1, Dengue, Zika, Influenza and respiratory syncytial virus. Its proprietary bacterial cell-based screening platform enables rapid screening for target viroporin proteins. The company was founded in February 1999 and is headquartered in North Ryde, Australia.
No news articles found for Biotron.
No data available for this period.
Currently no data to display
Currently no data to display.
Currently no data to display.
No data available for this period.
No data available for this period.
No data available for this period.
No data available for this period.
| Metric | YoY Change |
|---|
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
